Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual MeetingBusiness Wire • 04/09/24
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private PlacementBusiness Wire • 04/05/24
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer CenterBusiness Wire • 03/25/24
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business HighlightsBusiness Wire • 03/01/24
Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024Business Wire • 02/16/24
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw MethodBusiness Wire • 11/14/23
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual MeetingBusiness Wire • 10/03/23
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung CancerBusiness Wire • 09/07/23
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing CancerBusiness Wire • 08/22/23
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceBusiness Wire • 08/01/23
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung NodulesBusiness Wire • 07/12/23
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid ServicesBusiness Wire • 07/06/23